INTUITIVE SURGICAL INC

Intuitive Surgical operates in the robotic-assisted medical device industry, focusing on minimally invasive care through its da Vinci surgical systems and Ion endoluminal system. The company provides a comprehensive ecosystem that includes robotic-assisted systems, instruments and accessories, customer learning, and customer support services, all connected by a digital portfolio. The filing describes the Quintuple Aim as the company's 'north star,' focusing on better patient outcomes, better patient experiences, better care team experiences, lower total cost of care, and expanded access to high-quality minimally invasive care.

The filing names numerous competitors including Beijing Surgerii Robotics Company Limited, CMR Surgical Ltd., Distalmotion SA, Harbin Sizhe Rui Intelligent Medical Equipment Co., Ltd., Johnson & Johnson, Karl Storz SE & Co. KG, Medicaroid Corporation, Medtronic plc, meerecompany Inc., Noah Medical Corporation, Shandong Weigao Group Medical Polymer Company Ltd., Shanghai Microport Medbot (Group) Co., Ltd., Shenzhen Edge Medical Co., Ltd., and SS Innovations International, Inc. The company faces competition from existing open surgery, conventional MIS, drug therapies, radiation treatment, and other emerging diagnostic and interventional surgical approaches. The filing notes that domestic revenue accounted for 68% ¹ of total revenue, while revenue from OUS markets accounted for 32% ² of total revenue.

The company generates revenue through three primary streams: systems revenue from the sale or lease of da Vinci surgical systems and Ion endoluminal systems, instruments and accessories revenue from recurring sales of disposable and limited-use products, and service revenue from maintenance contracts and support. The filing describes a mix of transactional income from system sales and recurring revenue from instruments, accessories, and services. Primary customer segments include hospitals, healthcare facilities, and integrated delivery networks. The company utilizes a direct sales organization in the U.S., Europe, China (through joint ventures with Fosun Pharma), Japan, South Korea, India, Taiwan, and Canada, and uses distributors in other OUS markets.

The company's product lines include several models of the da Vinci surgical system: the fifth-generation da Vinci 5, fourth-generation da Vinci X, da Vinci Xi, and da Vinci SP surgical systems, and the third-generation da Vinci Si surgical system. The da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi ³. The Ion endoluminal system, cleared by the FDA in 2019 ⁴, is a flexible, robotic-assisted, catheter-based platform for minimally invasive biopsies in the lung. Instruments and accessories include da Vinci instruments with wristed joints, SureForm and EndoWrist staplers in 30, 45, and 60 mm sizes, the E-100 and E-200 electrosurgical generators, Vessel Sealer Extend and SynchroSeal energy instruments, and accessory products such as sterile drapes and vision products. The company also offers learning programs including Intuitive Learning and SimNow simulation platform, and digital solutions including My Intuitive, My Intuitive+, Case Insights, Telepresence, and Intuitive Hub.

The company's services include a network of field service engineers across the U.S., Canada, Europe, and Asia, offering installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring. Service revenue is generated through comprehensive service contracts and time and material programs. The company also offers perioperative consulting, Custom Hospital Analytics, and program analytics services. The digital portfolio includes 3D Modeling Services for augmented reality imaging in kidney, prostate, lung, and rectal procedures.

As of December 31, 2025, the company had approximately 17,021 ⁵ full-time employees, with approximately 2,288 ⁶ in research and development, 7,625 ⁷ in manufacturing operations, 4,837 ⁸ in commercial and service operations, and 2,271 ⁹ in administrative activities. During 2025, the number of employees increased by approximately 1,383 ¹⁰. The turnover rate was approximately 9.3% ¹¹. The company has contributed $240 million ¹² to the Intuitive Foundation since its inception. The company owned more than 5,600 ¹³ patents granted and still in force and more than 2,500 ¹⁴ patents pending worldwide as of December 31, 2025. The company manufactures systems in Sunnyvale, California, Peachtree Corners, Georgia, and at the Joint Venture's facility in Shanghai, China. Instruments and accessories are produced in Sunnyvale, California, and Mexicali, Mexico. Ion-related manufacturing occurs in Blacksburg, Virginia, and endoscope-related manufacturing in Parvomay, Bulgaria and at multiple sites in Germany.

Total revenue for the fiscal year ended December 31, 2025 was $8,354.0 million ¹⁵, compared to $7,564.0 million ¹⁶ in 2024 and $6,711.0 million ¹⁷ in 2023. Net income was $2,196.0 million ¹⁸ in 2025, compared to $1,801.0 million ¹⁹ in 2024 and $1,798.0 million ²⁰ in 2023. Diluted earnings per share was $6.14 ²¹ in 2025, compared to $4.98 ²² in 2024 and $4.93 ²³ in 2023. Gross profit margin was 66.8% ²⁴ in 2025, compared to 66.4% ²⁵ in 2024 and 66.5% ²⁶ in 2023. Cash and cash equivalents and investments were $5,314.0 million ²⁷ as of December 31, 2025.

The company focuses on expanding its da Vinci procedure business across five surgical specialties: general surgery, urologic surgery, gynecologic surgery, cardiothoracic surgery, and head and neck surgery. Key procedures include cholecystectomy, hernia repair, colorectal, bariatric, upper gastrointestinal, appendectomy, prostatectomy, partial nephrectomy, hysterectomy, sacrocolpopexy, lobectomy, and transoral surgery procedures. The company also focuses on minimally invasive biopsies in the lung through the Ion endoluminal system. The filing notes that in China, the 14th five-year plan quota published in June 2023 allows for the sale of 559 ²⁸ new surgical robots into China, which could include da Vinci surgical systems. In Japan, an additional eight da Vinci procedures were granted reimbursement in April 2022 ²⁹, and an additional five da Vinci procedures were granted reimbursement in April 2024 ³⁰, including lobectomy for benign conditions. The company received regulatory clearance for the da Vinci 5 surgical system in Japan in July 2025 ³¹ for use in all surgical specialties and procedures indicated for da Vinci Xi, except for cardiac indications.

The company continues to invest in research and development, with research and development expenses of $1,006.0 million ³² in 2025, compared to $912.0 million ³³ in 2024 and $801.0 million ³⁴ in 2023. The filing discusses the introduction of new products such as the da Vinci 5 surgical system featuring force feedback technology, the E-200 advanced electrosurgical generator, and the 8 mm SureForm 30 Curved-Tip stapler. The company also launched 3D Modeling Services as an augmented reality imaging product. The My Intuitive+ digital subscription package is available with the da Vinci 5 platform, including Case Insights, Telepresence, and SimNow 2.

The filing states that gross profit margins have fluctuated and are expected to continue to fluctuate due to factors including changes in customer, geographic, or product mix, changes in the mix of fixed-payment or usage-based operating lease arrangements, changes in the portion of sales involving trade-ins, introduction of new products, changes in pricing strategy, fluctuations in foreign currency exchange rates, competition, changes in production volume, changes in material and labor costs, changes to U.S. and foreign trade policies including tariffs, inventory obsolescence, and market conditions. The company expects gross profit margins to vary over time.

The company manufactures systems at facilities in Sunnyvale, California, Peachtree Corners, Georgia, and at the Joint Venture's facility in Shanghai, China. Instruments and accessories are produced in Sunnyvale, California, and Mexicali, Mexico. Ion-related manufacturing is in Blacksburg, Virginia, and endoscope-related manufacturing in Parvomay, Bulgaria and at multiple sites in Germany. The company purchases both custom and off-the-shelf components from a large number of suppliers, with some components provided by sole-sourced or single-sourced suppliers. The company generally purchases components through purchase orders rather than long-term supply agreements and does not maintain large volumes of finished goods relative to anticipated demand.

Research and development spending was $1,006.0 million ³⁵ in 2025. The company does not disclose specific capital expenditure plans, share repurchase authorization amounts, or dividend policy figures in the filing beyond what is reported in the financial statements. The company repurchased shares as part of its common stock repurchase program, with the program authorized on July 20, 2022 ³⁶.

The filing identifies several headwinds including the impact of tariffs on goods imported from Mexico where the company manufactures a significant majority of its instruments and accessories, from Germany where it manufactures a majority of its endoscopes, and from China where it imports certain materials. The filing notes that in 2025, the effects of China's anti-corruption campaign combined with competitive dynamics and industrial policy measures contributed to fewer systems being placed in China than anticipated. The filing also discusses that certain drugs initially approved for diabetes patients gained acceptance for weight loss treatment following FDA approvals, which has reduced the number of bariatric procedures performed, including those using the da Vinci surgical system.

The filing identifies macroeconomic conditions such as inflationary pressure, changes to monetary policy, elevated interest rates, volatile currency exchange rates, credit and sovereign debt concerns, concerns about slowed growth in China and other OUS markets, decreasing consumer confidence and spending, and global or local recessions as factors that could adversely impact demand for products. The filing also notes that in China, since 2022, several provinces have implemented significant limits on what hospitals can charge patients for surgeries using robotic surgical technology, which has impacted the number of procedures performed and pricing of instruments and accessories.

The company faces intense competition from established and emerging competitors including Johnson & Johnson, Medtronic plc, CMR Surgical Ltd., and others, with the risk that competitors may develop more effective or less expensive products, causing reduced revenue and loss of customers. The company is exposed to significant risks from operations outside the U.S., with OUS revenue accounting for 32% ³⁷ of total revenue, and faces risks including tariffs on goods imported from Mexico where a significant majority of instruments and accessories are manufactured, from Germany where a majority of endoscopes are manufactured, and from China where certain materials are imported. The company relies on sole- and single-sourced suppliers for components, and a disruption in supply could harm the ability to meet product demand. The company offers usage-based arrangements including leasing, exposing it to increased risk of revenue losses and credit risk if utilization falls short of anticipated levels. The company is subject to extensive FDA and foreign regulations, and failure to comply could result in significant enforcement actions including warning letters, fines, injunctions, product recalls, or criminal penalties.

Management's message emphasizes the company's mission that minimally invasive care is life-enhancing care and the vision of a future of care that is less invasive and profoundly better. The filing states that management has adopted the Quintuple Aim as the company's 'north star,' focusing on better patient outcomes, better patient experiences, better care team experiences, lower total cost of care, and expanded access to high-quality minimally invasive care. The strategic priorities emphasized include continuing to deliver innovative technology such as the da Vinci 5 surgical system with force feedback technology and more than 10,000 times the computing power of da Vinci Xi ³⁸, expanding the Ion endoluminal system for minimally invasive lung biopsies, and growing the digital portfolio including My Intuitive, My Intuitive+, Case Insights, Telepresence, and Intuitive Hub. Management also emphasizes the importance of clinical evidence, with the filing stating that the company seeks to demonstrate that its products can deliver better outcomes validated by rigorous, independent, and peer-reviewed evidence.